Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Oncolytic Virus
100%
Protoparvovirus
85%
Chimeric Virus
14%
Enhanced Anticancer Efficacy
14%
Scientific Expertise
14%
H-1PV
14%
Clinical Trials
14%
Tumor Cells
14%
Clinical Setting
14%
Tumor
14%
Treatment Combination
14%
Adenovirus
14%
Oncolysis
14%
Anticancer Properties
14%
Clinical Outcomes
14%
Combinational Therapy
14%
In Cancer
14%
Cancer Therapeutics
14%
Clinical Protocols
14%
Wild Type Virus
14%
Intrinsic Properties
14%
Blood-brain Barrier
14%
Further Development
14%
Antitumor Immune Response
14%
Cancer Patients
14%
Clinically Approved Drugs
14%
Parvovirus H-1
14%
Clinical Levels
14%
Immune Checkpoint Molecules
14%
Physiological Barriers
14%
Clinical Expertise
14%
Recurrent Glioblastoma multiforme
14%
Non-engineering
14%
Anticancer Strategy
14%
Size Nanoparticles
14%
Oncoselectivity
14%
Medicine and Dentistry
Oncolytic Virus
100%
Protoparvovirus
85%
Malignant Neoplasm
28%
Clinical Trial
14%
Glioblastoma
14%
Virus Typing
14%
Tumor Cell
14%
Blood Brain Barrier
14%
H-1 Parvovirus
14%
Immune Response
14%
Adenoviridae
14%
Nanoparticle
14%
Virus
14%
Tumor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Oncolytic Virus
100%
Protoparvovirus
85%
Malignant Neoplasm
28%
Virus
28%
Nanoparticle
14%
Glioblastoma
14%
Adenoviridae
14%
Clinical Trial
14%
H-1 Parvovirus
14%
Blood-Brain Barrier
14%